Irradiated KHYG-1 retains cytotoxicity: Potential for adoptive immunotherapy with a natural killer cell line

International Journal of Radiation Biology

Volumn 82, Issue 5, 2006, Pages 355-361

  Suck, G ^a,b,d   Branch, D ^b,c   Keating, A ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c CANADIAN BLOOD SERVICES   (Canada)

^d Johns Hopkins Singapore   (Singapore)

Author keywords

Adoptive immunotherapy; Cytotoxicity; Irradiation; KHYG 1; Natural killer cell line

Indexed keywords

GENE PRODUCT; PROTEIN KHYG1; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; GAMMA RADIATION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MYELOID LEUKEMIA; NATURAL KILLER CELL; PRIORITY JOURNAL; RADIATION DOSE; TARGET CELL;

CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEASIBILITY STUDIES; HL-60 CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; K562 CELLS; KILLER CELLS, NATURAL; RADIATION DOSAGE;

EID: 33745308438     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000600649653     Document Type: Article

References (13)

1. Gong JH, Maki G, Klingemann HG. 1994. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8:652-658.
2. Keating A, Martin P, Bernstein I, Papayannopoulou T, Raskind W, Singer J. 1983. EM-2 and EM-3: Two new Ph + myeloid cell lines. In: Golde DW, Marks PA, editors. Normal and Neoplastic Hematopoiesis, UCLA Symposia on Molecular and Cellular Biology, New Series 9. New York: Alan R. Liss. Inc. pp 513-520.
3. Klingemann HG, Wong E, Maki G. 1996. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biology of Blood and Marrow Transplantation 2:68-75.
4. Mahrus S, Kisiel W, Craik CS. 2004. Granzyme M is a regulatory protease that inactivates proteinase inhibitor 9, an endogenous inhibitor of granzyme B. Journal of Biological Chemistry 279:54275-54282.
5. Matsuo Y, Drexler HG. 2003. Immunoprofiling of cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma. Leukemia Research 27:935-945.
6. Ozdemir O, Ravindranath Y, Savasan S. 2003. Cell-mediated cytotoxicity evaluation using monoclonal antibody staining for target or effector cells with annexinV/propidium iodide colabeling by fluorosphere-adjusted counts on three-color flow cytometry. Cytometry 56A:53-60.
7. Raskind WH, Disteche CM, Keating A, Singer JW. 1987. Correlation between cytogenetic and molecular findings in human chronic myelogenous leukemia lines EM-2 and EM-3. Cancer Genetics and Cytogenetics 25:271-284.
8. Suck G, Branch DR, Smyth MJ, Miller RG, Vergidis J, Fahim S, Keating A. 2005. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Experimental Hematology 33:1160-1171.
9. Taguchi Y, Kondo T, Watanabe M, Miyaji M, Umehara H, Kozutsumi Y, Okazaki T. 2004. Interleukin-2-induced survival of natural killer (NK) cells involving phosphatidylinositol-3 kinase-dependent reduction of ceramide through acid sphingomyelinase, sphingomyelin synthase, and glucosylceramide synthase. Blood 104:3285-3293.
10. Tam YK, Maki G, Miyagawa B, Hennemann B, Tonn T, Klingemann HG. 1999. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Human Gene Therapy 10:1359-1373.
11. Tam YK, Martinson JA, Doligosa K, Klingemann HG. 2003. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy 5:259-272.
12. Tonn T, Becker S, Esser R, Schwabe D, Seifried E. 2001. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. Journal of Hematotherapy and Stem Cell Research 10:535-544.
13. Yagita M, Huang CL, Umehara H, Matsuo Y, Tabata R, Miyake M, Konaka Y, Takatsuki K. 2000. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 14: 922-930.